Total Payments
$1,093
2024 Payments
$45.04
Companies
18
Transactions
61
Medicare Patients
2,685
Medicare Billing
$392,937
Payment Breakdown by Category
Food & Beverage$1,093 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,093 | 61 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Valeant Pharmaceuticals North America LLC | $159.49 | 7 | $0 (2017) |
| PFIZER INC. | $144.92 | 3 | $0 (2018) |
| Depomed, Inc. | $134.77 | 6 | $0 (2017) |
| Purdue Pharma L.P. | $124.02 | 10 | $0 (2018) |
| Celgene Corporation | $109.54 | 6 | $0 (2018) |
| Amgen Inc. | $79.09 | 5 | $0 (2018) |
| Daiichi Sankyo Inc. | $53.69 | 4 | $0 (2018) |
| Janssen Pharmaceuticals, Inc | $45.04 | 2 | $0 (2024) |
| Takeda Pharmaceuticals America, Inc. | $37.88 | 3 | $0 (2017) |
| Lilly USA, LLC | $37.20 | 3 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $45.04 | 2 | Janssen Pharmaceuticals, Inc ($45.04) |
| 2018 | $388.75 | 20 | PFIZER INC. ($144.92) |
| 2017 | $659.05 | 39 | Valeant Pharmaceuticals North America LLC ($159.49) |
All Payment Transactions
61 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 07/31/2024 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Food and Beverage | In-kind items and services | $19.54 | General |
| Category: Neuroscience | ||||||
| 07/17/2024 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Food and Beverage | In-kind items and services | $25.50 | General |
| Category: Neuroscience | ||||||
| 10/25/2018 | PFIZER INC. | — | Food and Beverage | In-kind items and services | $124.98 | General |
| 09/18/2018 | Takeda Pharmaceuticals U.S.A., Inc. | Amitiza (Drug) | Food and Beverage | In-kind items and services | $7.39 | General |
| Category: Lower GI | ||||||
| 06/28/2018 | Lilly USA, LLC | FORTEO (Drug), TALTZ | Food and Beverage | In-kind items and services | $13.77 | General |
| Category: Bone Muscle Joint | ||||||
| 05/31/2018 | Regeneron Healthcare Solutions, Inc. | KEVZARA SARILUMAB INJECTION (Biological) | Food and Beverage | In-kind items and services | $20.04 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 05/24/2018 | UCB, Inc. | Cimzia (Drug) | Food and Beverage | In-kind items and services | $15.97 | General |
| Category: Immunology | ||||||
| 04/19/2018 | Regeneron Healthcare Solutions, Inc. | KEVZARA SARILUMAB INJECTION (Biological) | Food and Beverage | In-kind items and services | $12.59 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 04/12/2018 | PFIZER INC. | EMBEDA (Drug) | Food and Beverage | In-kind items and services | $8.22 | General |
| Category: NEUROSCIENCE;PAIN | ||||||
| 04/05/2018 | Celgene Corporation | — | Food and Beverage | In-kind items and services | $18.04 | General |
| 04/02/2018 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | RELISTOR ORAL (Drug) | Food and Beverage | In-kind items and services | $14.63 | General |
| Category: GASTROENTEROLOGY | ||||||
| 03/22/2018 | Amgen Inc. | Enbrel (Biological) | Food and Beverage | In-kind items and services | $20.31 | General |
| Category: Inflammation | ||||||
| 03/12/2018 | Purdue Pharma L.P. | SYMPROIC (Drug) | Food and Beverage | Cash or cash equivalent | $11.66 | General |
| Category: CONSTIPATION | ||||||
| 03/08/2018 | Purdue Pharma L.P. | SYMPROIC (Drug) | Food and Beverage | Cash or cash equivalent | $12.55 | General |
| Category: CONSTIPATION | ||||||
| 02/28/2018 | Daiichi Sankyo Inc. | Movantik (Drug) | Food and Beverage | In-kind items and services | $16.75 | General |
| Category: Opioid Induced Constipation | ||||||
| 02/20/2018 | Purdue Pharma L.P. | SYMPROIC (Drug) | Food and Beverage | Cash or cash equivalent | $13.80 | General |
| Category: CONSTIPATION | ||||||
| 02/07/2018 | Daiichi Sankyo Inc. | Movantik (Drug) | Food and Beverage | In-kind items and services | $14.26 | General |
| Category: Opioid Induced Constipation | ||||||
| 02/02/2018 | PFIZER INC. | EMBEDA (Drug) | Food and Beverage | In-kind items and services | $11.72 | General |
| Category: NEUROSCIENCE;PAIN | ||||||
| 02/01/2018 | Takeda Pharmaceuticals U.S.A., Inc. | Trintellix (Drug) | Food and Beverage | In-kind items and services | $12.86 | General |
| Category: Central Nervous System (CNS) | ||||||
| 01/25/2018 | Purdue Pharma L.P. | — | Food and Beverage | Cash or cash equivalent | $10.57 | General |
| 01/11/2018 | Lilly USA, LLC | FORTEO (Drug), TALTZ | Food and Beverage | In-kind items and services | $11.57 | General |
| Category: Bone Muscle Joint | ||||||
| 01/09/2018 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | RELISTOR ORAL (Drug) | Food and Beverage | In-kind items and services | $17.07 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/13/2017 | Daiichi Sankyo Inc. | Morphabond ER (Drug) | Food and Beverage | In-kind items and services | $11.30 | General |
| Category: Pain Management | ||||||
| 12/11/2017 | Purdue Pharma L.P. | SYMPROIC (Drug) | Food and Beverage | Cash or cash equivalent | $12.09 | General |
| Category: CONSTIPATION | ||||||
| 11/21/2017 | Takeda Pharmaceuticals America, Inc. | Amitiza (Drug) | Food and Beverage | In-kind items and services | $12.78 | General |
| Category: Lower GI | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 584 | 1,191 | $307,417 | $86,599 |
| 2022 | 12 | 681 | 1,297 | $322,164 | $101,834 |
| 2021 | 11 | 674 | 1,298 | $304,480 | $105,968 |
| 2020 | 15 | 746 | 1,378 | $310,058 | $98,536 |
Total Patients
2,685
Total Services
5,164
Medicare Billing
$392,937
Procedure Codes
48
All Medicare Procedures & Services
48 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 157 | 413 | $128,815 | $32,786 | 25.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 104 | 214 | $94,199 | $23,206 | 24.6% |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 2023 | 94 | 119 | $34,044 | $12,723 | 37.4% |
| 80307 | Testing for presence of drug, by chemistry analyzers | Office | 2023 | 111 | 145 | $15,200 | $8,016 | 52.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 28 | 28 | $15,093 | $4,436 | 29.4% |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 2023 | 13 | 14 | $5,481 | $2,148 | 39.2% |
| 90833 | Psychotherapy with evaluation and management visit, 30 minutes | Office | 2023 | 16 | 28 | $4,874 | $1,392 | 28.6% |
| 20610 | Aspiration and/or injection of fluid from large joint | Office | 2023 | 18 | 25 | $7,739 | $1,291 | 16.7% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2023 | 18 | 19 | $1,528 | $463.22 | 30.3% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 25 | 186 | $446.40 | $137.05 | 30.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 173 | 438 | $117,078 | $34,934 | 29.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 125 | 283 | $102,587 | $32,070 | 31.3% |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 2022 | 100 | 123 | $35,188 | $12,787 | 36.3% |
| 80307 | Testing for presence of drug, by chemistry analyzers | Office | 2022 | 118 | 150 | $15,564 | $8,492 | 54.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 34 | 34 | $17,132 | $5,042 | 29.4% |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 2022 | 19 | 20 | $7,830 | $2,794 | 35.7% |
| 90833 | Psychotherapy with evaluation and management visit, 30 minutes | Office | 2022 | 23 | 32 | $2,633 | $1,574 | 59.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 28 | 32 | $6,502 | $1,522 | 23.4% |
| 72148 | Mri scan of lower spinal canal without contrast | Office | 2022 | 13 | 13 | $11,746 | $1,080 | 9.2% |
| 20610 | Aspiration and/or injection of fluid from large joint | Office | 2022 | 15 | 21 | $4,447 | $1,069 | 24.0% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2022 | 13 | 14 | $1,128 | $355.36 | 31.5% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2022 | 20 | 137 | $328.80 | $114.87 | 34.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 166 | 434 | $112,636 | $36,624 | 32.5% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 120 | 260 | $91,021 | $31,152 | 34.2% |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 2021 | 101 | 127 | $36,332 | $13,623 | 37.5% |
About Dr. David Marks, MD
Dr. David Marks, MD is a Neurology healthcare provider based in Chapel Hill, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/01/2006. The National Provider Identifier (NPI) number assigned to this provider is 1760499933.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Marks, MD has received a total of $1,093 in payments from pharmaceutical and medical device companies, with $45.04 received in 2024. These payments were reported across 61 transactions from 18 companies. The most common payment nature is "Food and Beverage" ($1,093).
As a Medicare-enrolled provider, Marks has provided services to 2,685 Medicare beneficiaries, totaling 5,164 services with total Medicare billing of $392,937. Data is available for 4 years (2020–2023), covering 48 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Other Specialties Pain Medicine, Psychiatry
- Location Chapel Hill, NC
- Active Since 08/01/2006
- Last Updated 03/10/2025
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1760499933
Products in Payments
- RELISTOR ORAL (Drug) $191.19
- Nucynta (Drug) $134.77
- Enbrel (Biological) $66.43
- SYMPROIC (Drug) $50.10
- SPRAVATO (Drug) $45.04
- FORTEO (Drug) $37.20
- Amitiza (Drug) $34.47
- KEVZARA SARILUMAB INJECTION (Biological) $32.63
- Movantik (Drug) $31.01
- HYSINGLA ER (Drug) $27.78
- LORZONE (Drug) $24.82
- Trintellix (Drug) $23.66
- Morphabond ER (Drug) $22.68
- EMBEDA (Drug) $19.94
- ZOHYDRO ER (Drug) $16.65
- Cimzia (Drug) $15.97
- Otezla (Drug) $14.29
- Xtampza ER (Drug) $12.99
- Prolia (Biological) $12.66
- Evzio (Drug) $12.19
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Chapel Hill
James Howard, Md, MD
Neurology — Payments: $293,104
Neurology $293,104
Dr. O'neill D'cruz, Md, MD
Neurology — Payments: $129,393
Neurology $129,393
Dr. Rebecca Traub, M.d, M.D
Neurology — Payments: $113,803
Neurology $113,803
Dr. Eric Arehart, M.d, M.D
Neurology — Payments: $13,776
Neurology $13,776
Jing Wu, Md, MD
Neurology — Payments: $11,245
Neurology $11,245
Dr. Ana Felix, Md, MD
Neurology — Payments: $9,289
Neurology $9,289